https://www.optimumcomms.com/wp-content/uploads/2026/01/FundaMental-Pharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-17 08:59:542026-02-17 08:59:54FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
https://www.optimumcomms.com/wp-content/uploads/2026/01/FundaMental-Pharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-17 08:59:542026-02-17 08:59:54FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-17 08:31:212026-02-17 08:31:21Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026
https://www.optimumcomms.com/wp-content/uploads/2026/01/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-16 09:01:552026-02-16 09:01:55Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-16 08:40:572026-02-16 08:40:57Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
https://www.optimumcomms.com/wp-content/uploads/2025/10/AmacaThera_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-11 08:46:392026-02-12 10:34:06AmacaThera Named Life Sciences Ontario Emerging Company of the Year
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-11 06:07:262026-02-11 06:07:26Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2026/02/BOOSTPharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-10 13:45:292026-02-10 14:49:18Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-10 08:02:592026-02-10 08:02:59Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
https://www.optimumcomms.com/wp-content/uploads/2025/06/Breye-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-09 08:42:182026-02-09 08:42:18Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-05 08:40:212026-02-05 08:40:48Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 09:02:542026-01-29 09:02:54Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial
https://www.optimumcomms.com/wp-content/uploads/2026/01/Tecregen_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 08:36:262026-01-29 08:36:26TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 08:35:362026-01-29 08:35:36Biocomposites launches SYNICEM™ spacers in Canada
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 08:31:382026-01-29 08:31:38ViCentra Appoints Diabetes Commercialization Leader Reman McDonagh as Vice President, Global Marketing
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-28 08:37:542026-01-28 08:38:31Poolbeg Pharma plc – Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-26 12:22:352026-01-26 12:22:35Hansa Biopharma to host Year-end report 2025 conference callWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
